Loading clinical trials...
Loading clinical trials...
A Phase 1 Dose-Escalation Study of ADXS-NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Conditions
Interventions
ADXS-NEO
Pembrolizumab
Locations
5
United States
Honor Health
Scottsdale, Arizona, United States
UCLA
Los Angeles, California, United States
Ochsner Clinic Foundation - Ochsner Cancer Institute
New Orleans, Louisiana, United States
Atlantic Health System
Morristown, New Jersey, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Start Date
March 28, 2018
Primary Completion Date
October 24, 2019
Completion Date
November 12, 2020
Last Updated
February 24, 2023
NCT06996782
NCT06975293
NCT06343402
NCT06955988
NCT06512051
NCT06216301
Lead Sponsor
Advaxis, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions